- About us
- Clinical trials
- News & Publications
SOTIO receives orphan-drug designation for Ovarian Active Cellular Immunotherapy
SOTIO has received orphan-drug designation from the U.S. Food and Drug Administration (FDA) for the active cellular immunotherapy (ACI) DCVAC/OvCa.
SOTIO, LLC becomes a member of Massachusetts Biotechnology Council
SOTIO, LLC officially became a member of Massachusetts Biotechnology Council (MassBio), the largest biotechnology organization in Massachusetts.
SOTIO at ASCO Annual Meeting 2013
At this years annual meeting of the American Society of Clinical Oncology (ASCO) held from May 31 to June 4, in Chicago, Illinois; SOTIO will for the first time ever introduce itself to the worldwide oncology community.